I also believe #2 simply based on I believe leronlimab will be successful in cancer. Depending on the unknowns (sales price, royalty rate vs go alone, etc.) it could be better than Humira. If other indications pan out (mono, NASH, etc.) then it too crazy to think about.
(2)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.